Jade Biosciences, Inc. (NasdaqCM: JBIO)
Health Care · Biotechnology · US
$14.39
+1.91% today · +58.3% 1Y
Jade Biosciences, Inc. (NasdaqCM: JBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $915.17M and employs 55 people.
Over the last twelve months the share price has gained 58.3%, trading between 8.36 and 28.00.
Tweenvest scores Jade Biosciences, Inc. across four factors: quality 44/100, value 27/100. Its strongest factor is quality.
JBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $915.17M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.34
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $28.00
- 52-week low
- $8.36
- Avg volume (3M)
- —
- Shares outstanding
- 63.60M
- Employees
- 55
- Next earnings
- —
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
- ISIN
- US0080642061
- Listed since
- Jun 30, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Ingenia Therapeutics Inc.KOSDAQ: A950260 | $932.34M | ₩25,350.00 | -12.13% |
| LongBio Pharma (Suzhou) Co., Ltd.SEHK: 1779 | $926.52M | HK$98.00 | -3.64% |
| MoonLake ImmunotherapeuticsNasdaqCM: MLTX | $920.85M | $10.82 | +2.27% |
| Rigel Pharmaceuticals, Inc.NasdaqGS: RIGL | $916.81M | $49.08 | +0.74% |
| Odyssey Therapeutics, Inc.NasdaqCM: ODTX | $910.45M | $19.00 | -8.32% |
| Alphamab OncologySEHK: 9966 | $907.71M | HK$7.36 | -11.44% |
| Frontier Biotechnologies Inc.SHSE: 688221 | $886.38M | CN¥15.85 | -6.05% |
| Corvus Pharmaceuticals, Inc.NasdaqGM: CRVS | $884.95M | $10.52 | -3.49% |
Figures last refreshed Oct 11, 2026.